periodontal

ML324(IC50=920 nM) is a specific inhibitor of jumonji histone demethylase (JMJD2).

Flurbiprofen (dl-Flurbiprofen) is an anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.

Kgp-IN-1 is an arginine-specific gingipain (Rgp) inhibitor that targets and inhibits the activity of gingipains, which are proteases involved in periodontal disease.

LP-533401 hydrochloride is a peripheral Tph inhibitor that cannot cross the blood-brain barrier that inhibits 5-hydroxytryptamine synthesis and can be used to study periodontal disease and hepatic steatosis.

Human Immunoglobulin G (HumanIgG) is an immunoglobulin that plays a protective role in humoral immunity by generating antibody responses against specific pathogens, such as Bacteroides forsythus and Prevotella intermedia. It serves as an antibody standard for quantification in enzyme-linked immunosorbent assays (ELISA). Additionally, Human Immunoglobulin G antibody levels are utilized in research on rheumatoid arthritis (RA) and periodontal disease.

LPS-PG is a lipopolysaccharide from Porphyromonas gingivalis (P. gingivalis). It functions as a crucial virulence factor in the pathogenesis of periodontal disease by activating immune cells through Toll-like receptor 2 (TLR2), rather than the Escherichia coli (E. coli) receptor, Toll-like receptor 4 (TLR4). A lipoprotein from LPS-PG has been identified as the primary component responsible for TLR2-mediated cell activation.

XVA143, an α/β I-like allosteric antagonist, effectively blocks LFA-1-dependent firm adhesion while simultaneously increasing adhesion under shear flow and rolling conditions, both in vitro and in vivo.

Succinate/succinate receptor antagonist 1 is a potent succinate receptor antagonist. Succinate/succinate receptor antagonist 1 interrupts succinate signals in gingival tissue and inhibits the activation of SucnRl Antagonist 1. Its IC50 value is 20 μsouth of the coast. Succinate/succinate receptor antagonist 1 can be used to treat periodontal disease.

Flurbiprofen sodium is an anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting carbonic anhydrase.

Oleanolic aldehyde, an antimicrobial agent, effectively hinders the growth of oral pathogens Streptococcus mutans and Porphyromonas gingivalis, implicated in dental caries and periodontal disease. The compound exhibits minimum inhibitory concentrations (MICs) of 488 µg/mL and 250 µg/mL against these bacteria respectively [1].

CaⅡ-EDTA disodium dihydrate (Calcium disodium EDTA dihydrate) serves as an orally active metal chelating agent, displaying bactericidal properties against periodontal pathogens such as Aggregatibacter actinomycetemcomitans, Prevotella intermedia, and Porphyromonas gingivalis [1]. Additionally, it is recognized as an effective chelating antidote for lead and cadmium poisoning [2] [3].

6,4'-Dihydroxy-7-methoxyflavanone is a biologically active compound isolated from the heartwood of Dalbergia odorifera T. Chen (Leguminosae) with antioxidant, anti-inflammatory and neuroprotective effects. 6,4'-Dihydroxy-7-methoxyflavanone can be used in studies about the treatment of osteoclastogenic bone diseases such osteoporosis, rheumatoid arthritis and periodontal diseases.